FDA Export Reform

HEHS-96-60R: Published: Dec 21, 1995. Publicly Released: Dec 21, 1995.

Additional Materials:


Office of Public Affairs
(202) 512-4800

Pursuant to a congressional request, GAO reviewed proposed drug export legislation that would allow the export of drugs not approved by the Food and Drug Administration (FDA), focusing on the: (1) criteria that Congress could use to identify whether countries have adequate drug regulatory systems; and (2) implications of applying those criteria to other countries. GAO noted that: (1) the World Health Organization's (WHO) existing information system is adequate to identify criteria to assess countries' pharmaceutical regulatory systems; (2) countries that meet the export criteria should have adequate drug laws and regulatory bodies that oversee pharmaceutical activities, a drug registry, and drug quality assurance and adverse drug reaction (ADR) systems; (3) most of the countries with the largest economies meet the export criteria, but many do not have formal ADR systems; (4) most countries rely on the exporting country's regulatory authority to certify an exported drug's registration and sales authorization because they lack a comprehensive quality assurance system; (5) since non-FDA approved drugs are not freely marketed in the United States, non-tier I importing countries will have to rely on their own or other countries' quality assurance systems; and (6) WHO will complete 2 additional studies that will provide further information on countries' drug regulatory systems and identify essential evaluation criteria.

Oct 26, 2020

Oct 19, 2020

Oct 8, 2020

Oct 1, 2020

Sep 30, 2020

Sep 23, 2020

Sep 21, 2020

Sep 17, 2020

Sep 16, 2020

Sep 14, 2020

Looking for more? Browse all our products here